PMID: 28105286

Authors:

Erra M, Taltavull J, Greco A, Bernal FJ, Caturla JF, Gracia J, Dominguez M, Sabate M, Paris S, Soria S, Hernandez B, Armengol C, Cabedo J, Bravo M, Calama E, Miralpeix M, Lehner MD

Title:

Discovery of a Potent, Selective, and Orally Available PI3Kdelta Inhibitor for the Treatment of Inflammatory Diseases.

Journal:

ACS Med Chem Lett. 2016 Nov 30;8(1):118-123. doi: 10.1021/acsmedchemlett.6b00438., eCollection 2017 Jan 12.

Abstract:

The delta isoform of the phosphatidylinositol 3-kinase (PI3Kdelta) has been shown to have an essential role in specific immune cell functions and thus represents a potential therapeutic target for autoimmune and inflammatory diseases. Herein, the optimization of a series of pyrrolotriazinones as potent and selective PI3Kdelta inhibitors is described. The main challenge of the optimization process was to identify an orally available compound with a good pharmacokinetic profile in preclinical species that predicted a suitable dosing regimen in humans. Structure-activity relationships and structure-property relationships are discussed. This medicinal chemistry exercise led to the identification of LAS191954 as a candidate for clinical development.